KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $256.4 million.

  • Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) fell 65.87% to $256.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.4 million, marking a year-over-year decrease of 65.87%. This contributed to the annual value of $257.9 million for FY2024, which is 7.76% up from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $256.4 million, which was down 65.87% from $256.8 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $259.4 million during Q1 2021, and its lowest value of $255.1 million during Q1 2022.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $257.7 million (2021), whereas its average is $257.5 million.
  • In the last 5 years, Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) plummeted by 165.77% in 2022 and then skyrocketed by 90.16% in 2023.
  • Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $257.7 million in 2021, then fell by 0.62% to $256.1 million in 2022, then grew by 0.62% to $257.7 million in 2023, then increased by 0.08% to $257.9 million in 2024, then fell by 0.58% to $256.4 million in 2025.
  • Its last three reported values are $256.4 million in Q3 2025, $256.8 million for Q2 2025, and $256.9 million during Q1 2025.